JPS5144499B1
(es)
|
1970-08-29 |
1976-11-29 |
|
|
JPS5824836B2
(ja)
|
1974-10-14 |
1983-05-24 |
ノウミボウサイコウギヨウ カブシキガイシヤ |
カサイナドノツウホウソウチ
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
ES521371A0
(es)
|
1982-04-12 |
1984-05-16 |
Hybritech Inc |
Un procedimiento para la purificacion de un anticuerpo.
|
US4689299A
(en)
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
JPS6350741A
(ja)
|
1986-08-20 |
1988-03-03 |
Nippon Tectron Co Ltd |
蛍光偏光分析装置
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
CA2006684C
(en)
|
1988-12-30 |
1996-12-17 |
Charles T. Esmon |
Monoclonal antibody against protein c
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインcの分離方法
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1991012023A2
(en)
|
1990-02-16 |
1991-08-22 |
Boston Biomedical Research Institute |
Hybrid reagents capable of selectively releasing molecules into cells
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
EP0564531B1
(en)
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
US5795965A
(en)
|
1991-04-25 |
1998-08-18 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human to human interleukin-6 receptor
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
RO118524B1
(ro)
|
1992-11-13 |
2003-06-30 |
Idec Pharmaceuticals Corp San |
Metoda pentru tratarea unei tulburari legata de celulele b
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
ATE322547T1
(de)
|
1993-06-10 |
2006-04-15 |
Genetic Therapy Inc |
Adenovirale vektoren für die behandlung der hämophilie
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
CN101601861A
(zh)
|
1994-10-07 |
2009-12-16 |
中外制药株式会社 |
以il-6拮抗剂作为有效成分治疗慢性类风湿性关节炎
|
DE4436561C1
(de)
|
1994-10-13 |
1996-03-14 |
Deutsche Spezialglas Ag |
Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
|
WO1996012503A1
(fr)
|
1994-10-21 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Remede contre des maladies provoquees par la production d'il-6
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
IL127872A0
(en)
|
1996-07-19 |
1999-10-28 |
Amgen Inc |
Analogs of cationic proteins
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
HU226175B1
(en)
|
1997-04-17 |
2008-06-30 |
Amgen Inc |
Human ob protein suspension, process for producing thereof and use for production of pharmaceutical composition
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
CN1277632A
(zh)
|
1997-10-03 |
2000-12-20 |
中外制药株式会社 |
天然人源化抗体
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
PT1034298E
(pt)
|
1997-12-05 |
2012-02-03 |
Scripps Research Inst |
Humanização de anticorpo murino
|
WO1999051642A1
(en)
|
1998-04-02 |
1999-10-14 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
IL138801A0
(en)
|
1998-04-03 |
2001-10-31 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor and process for the preparation thereof
|
EP1071700B1
(en)
|
1998-04-20 |
2010-02-17 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
AU770555B2
(en)
|
1998-08-17 |
2004-02-26 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
ATE477273T1
(de)
|
1998-12-01 |
2010-08-15 |
Facet Biotech Corp |
Humanisierte antikoerper gegen gamma-interferon
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
DK2270147T4
(da)
|
1999-04-09 |
2020-08-31 |
Kyowa Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
CA2385347C
(en)
|
1999-10-04 |
2009-12-15 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
CA2393869A1
(en)
|
1999-12-15 |
2001-06-21 |
Genetech,Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
DK1242438T3
(da)
|
1999-12-29 |
2007-02-12 |
Immunogen Inc |
Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
|
US20020004587A1
(en)
|
2000-04-11 |
2002-01-10 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
HUP0301835A2
(hu)
|
2000-05-03 |
2003-09-29 |
Mbt Munich Biotechnology Ag |
Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CN103333860B
(zh)
|
2000-10-06 |
2015-07-08 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
ES2333775T3
(es)
|
2000-10-10 |
2010-03-01 |
Genentech, Inc. |
Inhibicion de la activacion del complemento c5 para el tratamiento y la prevencion de rechazo de xenoinjerto retrasado o rechazo vascular agudo.
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
DE60143544D1
(de)
|
2000-12-12 |
2011-01-05 |
Medimmune Llc |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
US7358054B2
(en)
|
2001-04-13 |
2008-04-15 |
Biogen Idec Ma Inc. |
Antibodies to VLA-1
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
EP1780273B1
(en)
|
2001-06-22 |
2010-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
KR20040054669A
(ko)
|
2001-08-03 |
2004-06-25 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
US7432356B2
(en)
|
2001-08-17 |
2008-10-07 |
Genentech, Inc. |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
BRPI0214168B8
(pt)
|
2001-11-14 |
2021-05-25 |
Centocor Inc |
anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US6684637B2
(en)
|
2002-01-25 |
2004-02-03 |
Sunpower, Inc. |
Parallel slot heat exchanger
|
KR20040082421A
(ko)
|
2002-02-11 |
2004-09-24 |
제넨테크, 인크. |
빠른 항원 결합 속도를 갖는 항체 변이체
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
AU2003217912A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
EP1502603A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
WO2003085118A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003248652A1
(en)
|
2002-06-12 |
2003-12-31 |
Genencor International, Inc. |
Methods for improving a binding characteristic of a molecule
|
WO2003105757A2
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
AU2003264009A1
(en)
|
2002-08-15 |
2004-03-03 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
CA2510003A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1608684A2
(en)
|
2003-02-07 |
2005-12-28 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
AU2004215653B2
(en)
|
2003-02-28 |
2011-03-17 |
Lonza Biologics Plc. |
Antibody purification by protein A and ion exchange chromatography
|
KR20060026004A
(ko)
|
2003-02-28 |
2006-03-22 |
안티제닉스 아이엔씨 |
당단백질 및 항원성 분자의 올리고머화를 조장하는 렉틴의용도
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
PL1631313T3
(pl)
|
2003-06-05 |
2015-08-31 |
Genentech Inc |
Terapia skojarzona zaburzeń z komórek B
|
EP1663306A2
(en)
|
2003-09-05 |
2006-06-07 |
Genentech, Inc. |
Antibodies with altered effector functions
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
WO2005035778A1
(ja)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
SI2380911T1
(en)
|
2003-11-05 |
2018-07-31 |
Roche Glycart Ag |
ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
|
WO2005049649A1
(en)
|
2003-11-05 |
2005-06-02 |
Ares Trading S.A. |
Process for the purification of il-18 binding protein
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
PL2418220T3
(pl)
|
2003-12-10 |
2017-12-29 |
E. R. Squibb & Sons, L.L.C. |
Przeciwciała przeciwko interferonowi alfa i ich zastosowania
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
BRPI0506679A
(pt)
|
2004-02-11 |
2007-05-15 |
Warner Lambert Co |
métodos de tratar osteoartrite com antagonistas de il-6
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
KR101245983B1
(ko)
|
2004-03-31 |
2013-06-28 |
제넨테크, 인크. |
인간화 항-tgf-베타 항체
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
NZ578643A
(en)
|
2004-04-13 |
2010-11-26 |
Hoffmann La Roche |
Anti-P-selectin antibodies
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
WO2006009901A2
(en)
|
2004-06-18 |
2006-01-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
JP2008504289A
(ja)
|
2004-06-25 |
2008-02-14 |
メディミューン,インコーポレーテッド |
部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
|
PL2471813T3
(pl)
|
2004-07-15 |
2015-09-30 |
Xencor Inc |
Zoptymalizowane warianty Fc
|
CA2573192C
(en)
|
2004-08-04 |
2013-09-10 |
Applied Molecular Evolution Inc. |
Variant fc regions
|
WO2006031825A2
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
US20080233131A1
(en)
|
2004-09-14 |
2008-09-25 |
Richard John Stebbings |
Vaccine
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
RU2440582C2
(ru)
|
2004-12-23 |
2012-01-20 |
Ново Нордиск А/С |
Аффинные лиганды, связывающие антитела
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
TW200714313A
(en)
|
2005-04-08 |
2007-04-16 |
Chugai Pharmaceutical Co Ltd |
Antibodies that substitute for coagulation factor VIII
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
BRPI0614893A2
(pt)
|
2005-08-19 |
2010-03-30 |
Wyeth Corp |
anticorpo isolado capaz de ligar gdf-8, polinucleotìdeo isolado, célula hospedeira, vetor, método para produzir um anticorpo, in vitro para diagnosticar ou detectar se um paciente está sofrendo de um distúrbio associado com gdf-8 para monitorar a severidade de um distúrbio associado com gdf-8 e para prognosticar a possibilidade de que um paciente irá desenvolver um distúrbio associado com gdf-8, anticorpo isolado e purificado, composição farmacêutica para tratar, melhorar e/ ou prevenir um distúrbio associado com gdf-8, e, usos de uma quantidade eficaz do anticorpo e do polinucleotìdeo
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
EP1959997A4
(en)
|
2005-11-28 |
2009-12-23 |
Medimmune Llc |
ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CN101330923B
(zh)
*
|
2005-12-12 |
2015-01-07 |
Ac免疫有限公司 |
治疗性疫苗
|
EP3219328B1
(en)
|
2005-12-29 |
2020-06-17 |
Janssen Biotech, Inc. |
Human anti-il-23 antibodies, compositions, method and uses
|
WO2007103134A2
(en)
|
2006-03-02 |
2007-09-13 |
Alexion Pharmaceuticals, Inc. |
Prolongation of survival of an allograft by inhibiting complement activity
|
RU2477137C2
(ru)
|
2006-03-08 |
2013-03-10 |
АРКЕМИКС Эл Эл Си |
Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
|
PL3167888T3
(pl)
|
2006-03-15 |
2024-08-26 |
Alexion Pharmaceuticals, Inc. |
Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
|
CN101479381B
(zh)
|
2006-03-31 |
2015-04-29 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
AU2007235484B2
(en)
|
2006-04-05 |
2013-11-07 |
Abbvie Biotechnology Ltd |
Antibody purification
|
JP2009536527A
(ja)
|
2006-05-09 |
2009-10-15 |
ジェネンテック・インコーポレーテッド |
最適化されたスキャフォールドを備えた結合ポリペプチド
|
US9028821B2
(en)
|
2006-06-08 |
2015-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
|
ES2399075T3
(es)
|
2006-08-30 |
2013-03-25 |
Genentech, Inc. |
Anticuerpos multiespecíficos
|
CA2665287C
(en)
|
2006-10-06 |
2022-08-30 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Prevention of tissue ischemia, related methods and compositions
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
MX2009010181A
(es)
*
|
2007-03-22 |
2009-12-04 |
Novartis Ag |
Antigenos c5 y usos de los mismos.
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
CA2691974C
(en)
|
2007-06-29 |
2016-08-30 |
Quest Diagnostics Investments Incorporated |
Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
|
CN101939425B
(zh)
|
2007-09-26 |
2014-05-14 |
中外制药株式会社 |
抗il-6受体抗体
|
EP2202245B1
(en)
|
2007-09-26 |
2016-08-24 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
CN101874041B
(zh)
|
2007-09-26 |
2013-06-19 |
中外制药株式会社 |
抗体恒定区修饰体
|
MY148637A
(en)
|
2007-09-28 |
2013-05-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3 antibody having improved kinetics in plasma
|
EP2261254A3
(en)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
TW201447062A
(zh)
|
2008-04-11 |
2014-12-16 |
Chugai Pharmaceutical Co Ltd |
重複結合複數個抗原的抗原結合分子
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
US20090312673A1
(en)
|
2008-06-14 |
2009-12-17 |
Vytronus, Inc. |
System and method for delivering energy to tissue
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
SI2894165T1
(sl)
|
2008-11-10 |
2023-04-28 |
Alexion Pharmaceuticals, Inc. |
Postopki in sestavki za zdravljenje motenj povezanih s komplementom
|
EP2400981A4
(en)
|
2009-02-26 |
2013-02-27 |
Lpath Inc |
DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
CN101875696B
(zh)
*
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
JP6101489B2
(ja)
|
2010-01-28 |
2017-03-22 |
アブ バイオサイエンシズ インコーポレイテッド |
親和性が低下した抗体およびそれを作製する方法
|
ES2615732T3
(es)
*
|
2010-03-01 |
2017-06-08 |
Alexion Pharmaceuticals, Inc. |
Composiciones para tratar la enfermedad de Degos
|
TW201206466A
(en)
*
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
EA201291133A1
(ru)
|
2010-04-30 |
2013-04-30 |
Алексион Фармасьютикалз, Инк. |
Антитела, обладающие пониженной иммуногенностью в организме человека
|
KR102385507B1
(ko)
|
2010-11-30 |
2022-04-12 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
CA2822288A1
(en)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Anti-c5/c5a/c5adesr antibodies and fragments
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
SMT201900239T1
(it)
|
2011-05-21 |
2019-05-10 |
Macrogenics Inc |
Molecole di legame a cd3 in grado di legare cd3 umano e non umano
|
CN103826659A
(zh)
*
|
2011-06-20 |
2014-05-28 |
圣路易斯大学 |
用于治疗的靶向神经肌肉接头
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
|
EP3517550A1
(en)
|
2011-11-30 |
2019-07-31 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
CN104244980B
(zh)
|
2012-02-24 |
2017-11-10 |
中外制药株式会社 |
经由FcγIIB促进抗原消除的抗原结合分子
|
CN107361011B
(zh)
|
2012-03-16 |
2021-08-27 |
瑞泽恩制药公司 |
制备表达ph敏感性免疫球蛋白序列的非人动物的方法
|
CA2865643A1
(en)
*
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
|
HUE037613T2
(hu)
*
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
TWI619729B
(zh)
*
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
WO2013180201A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
JP6309521B2
(ja)
*
|
2012-08-13 |
2018-04-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
pH依存性結合特性を有する抗PCSK9抗体
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
TW201418707A
(zh)
*
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
KR101638931B1
(ko)
|
2013-01-31 |
2016-07-12 |
서울대학교산학협력단 |
보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
US20160032014A1
(en)
|
2013-03-15 |
2016-02-04 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
WO2014160958A1
(en)
|
2013-03-29 |
2014-10-02 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
US20160184391A1
(en)
|
2013-08-16 |
2016-06-30 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
JP6382641B2
(ja)
|
2013-09-11 |
2018-08-29 |
株式会社東芝 |
非水電解質電池及び非水電解質電池の製造方法
|
AU2015218903B2
(en)
|
2014-02-20 |
2020-10-15 |
Allergan, Inc. |
Complement component C5 antibodies
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
JP2016024424A
(ja)
|
2014-07-24 |
2016-02-08 |
株式会社リコー |
情報処理システム、情報処理装置、情報処理方法、及びプログラム
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
TW202248212A
(zh)
|
2015-02-05 |
2022-12-16 |
日商中外製藥股份有限公司 |
包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
|
ES2967627T3
(es)
|
2015-02-27 |
2024-05-03 |
Chugai Pharmaceutical Co Ltd |
Composición para tratar enfermedades relacionadas con IL-6
|
WO2016160756A2
(en)
|
2015-03-31 |
2016-10-06 |
Alexion Pharmaceuticlas, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents
|
WO2016178980A1
(en)
|
2015-05-01 |
2016-11-10 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
|
JP2018520139A
(ja)
|
2015-06-26 |
2018-07-26 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
DK3390442T5
(da)
|
2015-12-18 |
2024-09-23 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
WO2017123636A1
(en)
|
2016-01-11 |
2017-07-20 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
US20190085095A1
(en)
|
2016-01-25 |
2019-03-21 |
Shire Human Genetic Therapies, Inc. |
Anti-c5 antibodies with enhanced ph switch
|
IL263481B2
(en)
|
2016-06-14 |
2024-06-01 |
Regeneron Pharma |
Antibodies against C5 and their uses
|
IL300611A
(en)
|
2016-06-17 |
2023-04-01 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antibodies and methods for their use
|
CR20220563A
(es)
|
2017-01-31 |
2022-12-07 |
Chugai Pharmaceutical Co Ltd |
Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
|
SG11201907848YA
(en)
|
2017-03-14 |
2019-09-27 |
Five Prime Therapeutics Inc |
Antibodies binding to vista at acidic ph
|
AU2018235031B2
(en)
|
2017-03-16 |
2021-08-12 |
Medimmune Limited |
Anti-PAR2 antibodies and uses thereof
|
DK3411400T3
(da)
|
2017-04-03 |
2021-10-11 |
Inflarx Gmbh |
Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
|
US12128101B2
(en)
|
2017-10-26 |
2024-10-29 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
|
US20210000927A1
(en)
|
2017-12-04 |
2021-01-07 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
TWI701041B
(zh)
|
2018-08-01 |
2020-08-11 |
日商中外製藥股份有限公司 |
在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
|